Abstract:Cytotoxic CD8 T cells are the canonical mediators of tumor clearance by the adaptive immune system. As such, current immunotherapies, including immune checkpoint blockade (ICB), target exhausted CD8 T cells with the hope of reinvigorating the CD8 T cells to drive tumor clearance. However, many tumors, including pancreatic ductal adenocarcinoma (PDAC), can evade CD8 T cell detection via downregulation of the antigen presentation molecule, major histocompatibility complex I (MHC I) as either primary or acquired resistance to immunotherapy. We have previously reported that agonistic CD40 antibody (αCD40), which promotes the maturation and licensing of dendritic cells to drive T cell priming, synergizes with ICB to induce tumor rejection dependent on both CD4 and CD8 T cells in mouse models of PDAC. Given the potential mechanisms of resistance to CD8 T cell immunity, we hypothesized that interrogation of the mechanisms underlying αCD40-induced CD4 T cell rejection of PDAC will reveal targets for improving CD4 T cell-directed immunotherapies. Here, we show that implantation of an MHC I deficient PDAC cell line derived from the genetically engineered KrasG12DTrp53R172HPdx1-Cre (KPC) mouse model results in normal tumor establishment and progression. Upon treatment with combined αCD40 and ICB, tumor growth was significantly decreased in a CD4, but not CD8, T cell-dependent manner. Using genetic knockout mice, we determined that tumor regression was perforin-independent and identified host expression of IFNγ as requisite for therapeutic efficacy. To identify the cellular subset mediating CD4 T cell-rejection of the tumor, we assessed the major histocompatibility complex II (MHC II) positive cells in the tumor microenvironment (TME), which possess the ability to directly synapse with CD4 T cells to drive anti-tumorigenic T cell programs. We determined that macrophage and myeloid cells were dispensable for treatment efficacy, however non-immune cells in the TME can also interact with CD4 T cells through expression of MHC II. Interrogation of stromal cells reveals an increase in the proportion of MHC II+ subsets after combined αCD40/ICB treatment, with a concomitant decrease in the proportion of MHC II+ tumor cells. These data support the notion that CD4 T cell control of tumors may be mediated by both direct and indirect mechanisms of tumor killing. Findings from this work will elucidate non-canonical mechanisms of CD4 T cell-mediated rejection of tumors and may be leveraged to discover novel translational targets for immunotherapy. Citation Format: Margaret E. Haerr, Samuel I. Kim, Charu Arora, Kyle P. Gribbin, Robert H. Vonderheide, Katelyn T. Byrne. CD40 agonism induces CD4 T cell mediated rejection of major histocompatibility complex class I deficient pancreatic tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6597.

Sufficiency of CD40 activation and immune checkpoint blockade for T cell priming and tumor immunity

Cancer immunotherapy via synergistic coactivation of myeloid receptors CD40 and Dectin-1

Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma

Induction of cytotoxic effector cells towards cholangiocellular, pancreatic, and colorectal tumor cells by activation of the immune checkpoint CD40/CD40L on dendritic cells

Abstract 6597: CD40 agonism induces CD4 T cell mediated rejection of major histocompatibility complex class I deficient pancreatic tumors

CD40-activated B cells induce anti-tumor immunity in vivo

Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment

Mechanisms of CD40-dependent cDC1 licensing beyond costimulation

OX40/OX40 ligand and its role in precision immune oncology

Cytotoxic chemotherapy potentiates the immune response and efficacy of combination CXCR4/PD-1 inhibition in models of pancreatic ductal adenocarcinoma

CD200 promotes immunosuppression in the pancreatic tumor microenvironment

Combination of Radiotherapy and Vaccination Overcomes Checkpoint Blockade Resistance

PD-1/CTLA-4 blockade leads to expansion of CD8+PD-1int TILs and results in tumor remission in experimental liver cancer

The CD58-CD2 axis is co-regulated with PD-L1 via CMTM6 and shapes anti-tumor immunity.

Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses

Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties

Tumor Infiltrating T Cell States and Checkpoint Inhibitor Expression in Hepatic and Pancreatic Malignancies

492 Integration of High Dimensional Datasets in an Immunocompetent Mammary Mouse Model Reveals Pathways of Tolerance and Resistance to Immune Checkpoint Blockade

SUMO Inhibition Plus CD40 Agonism Increases Anti-Tumor Immunogenicity Through Interferon Mediated Macrophage Activation

The interaction of CD4+ helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response

Harnessing the potential of CD40 agonism in cancer therapy